Callitas Health, Inc., Signs a Definitive Patent Technology Assignment Agreement to Acquire Additional Novel Cannabis Dosing Technologies

Author's Avatar
Apr 12, 2019
Article's Main Image

CINCINNATI, OH / ACCESSWIRE / October 2, 2018 / Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the ''Company'' or ''Callitas'') an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that it signed a definitive Patent Technology Assignment Agreement with Ronald J. Thompson, MD to expand its cannabis delivery technology portfolio. The new intellectual property acquired (four separate patent applications) will cover various novel oral and ingestible products including those for orally dissolving immediate cannabis effect, sustained release cannabis effect, and a combination of both. It will also cover products for the appropriate individual controlled dosing of CBD and/or THC for the legal, adult use and medical marijuana markets.